OmniAb Inc
NASDAQ:OABI
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.25
3.88
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
O
|
OmniAb Inc
NASDAQ:OABI
|
270.6m USD |
Loading...
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1.3T USD |
Loading...
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
233.5B USD |
Loading...
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
166.5B USD |
Loading...
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.9T KRW |
Loading...
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
37.9B CHF |
Loading...
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41B USD |
Loading...
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
274.7B CNY |
Loading...
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
38.2B USD |
Loading...
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
29.1B USD |
Loading...
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.2B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
OmniAb Inc
Glance View
OmniAb, Inc. operates as a drug discovery company. The company is headquartered in Emeryville, California and currently employs 93 full-time employees. The company went IPO on 2020-10-09. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. Its OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach and OmniTaur features structural attributes of cow antibodies for complex targets. The firm's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic targets.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for OmniAb Inc is -342.3%, which is below its 3-year median of -230.7%.
Over the last 3 years, OmniAb Inc’s Operating Margin has decreased from -104.5% to -342.3%. During this period, it reached a low of -396.8% on Mar 31, 2024 and a high of -40.5% on Mar 31, 2023.